Page last updated: 2024-12-08
3-methyleneindolenine
Description
3-methyleneindolenine: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
3-methyleneindolenine : An indole that consists of 3H-indole bearing a methylene substituent at position 3. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
ID Source | ID |
PubMed CID | 170404 |
CHEBI ID | 63905 |
SCHEMBL ID | 5488008 |
MeSH ID | M0256931 |
Synonyms (11)
Synonym |
40642-83-9 |
3-methyleneindolenine |
3-methylene-3h-indole |
3-methylene-indolenine |
3h-indole, 3-methylene- |
CHEBI:63905 |
SCHEMBL5488008 |
3-methylidene-3h-indole |
DTXSID00193643 |
3-methyleneindole |
Q27132906 |
Research Excerpts
Toxicity
Dosage Studied
Excerpt | Relevance | Reference |
"In responding to Drs Calabrese and Baldwin's question, 'At what point, if ever, should hormesis be employed as the principal dose response default assumption in risk assessment?', we examined the benefits of replacing traditional dose-response with hormesis." | ( Examining the risks and benefits of replacing traditional dose-response with hormesis. Oehme, FW; Pickrell, JA, 2005) | 0.33 |
"In examining traditional dose-response and hormesis, we have considered the case examples of pulmonary hyperplasia following inhalation of carbon black and pulmonary hyperplasia after methyleneindolenine (3MEIN) exposures, development of irreversible pulmonary fibrosis, effect of continuous exercise and low-level lead exposures, and colorectal cancer." | ( Examining the risks and benefits of considering both the traditional dose--response and hormesis in arriving at an acceptable exposure level. Oehme, FW; Pickrell, JA, 2006) | 0.33 |
Roles (1)
Role | Description |
metabolite | Any intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites. |
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Drug Classes (1)
Class | Description |
indoles | Any compound containing an indole skeleton. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (9)
Timeframe | Studies, This Drug (%) | All Drugs % |
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (22.22) | 18.2507 |
2000's | 5 (55.56) | 29.6817 |
2010's | 2 (22.22) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.30
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
Metric | This Compound (vs All) |
---|
Research Demand Index | 12.30 (24.57) | Research Supply Index | 2.30 (2.92) | Research Growth Index | 4.60 (4.65) | Search Engine Demand Index | 0.00 (26.88) | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 9 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |